- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
LG Debuts 5MP High-Definition Mammography Monitor
Intended for mammography and digital breast tomosynthesis (DBT) interpretation, the device reportedly emphasizes high-definition image quality and ease of use for radiologists.
Offering enhanced visualization of mammography and other breast imaging, LG has launched the 21HQ613D-B diagnostic monitor, which allow for high-definition views on a 21.3-inch, 5-megapixel (MP) platform.
Emphasizing the image quality of the 21HQ613D-B device, LG noted the monitor, which received FDA clearance in February 2024, gives radiologists 2,048 x 2,560 resolution, 1,100 cd/m2 luminance and an 1800:1 contrast ratio.
Cleared by the FDA in February 2024, the newly launched 21HQ613D-B diagnostic monitor offers radiologists 2,048 x 2,560 resolution, 1,100 cd/m2 luminance and an 1800:1 contrast ratio, according to LG, the manufacturer of the device. (Image courtesy of LG.)
While the 21HQ613D-B diagnostic monitor is intended for the assessment of digital mammography and digital breast tomosynthesis (DBT), LG noted that radiologists can also utilize the monitor for review of breast magnetic resonance imaging (MRI), computed tomography (CT) or ultrasound images.
The 21HQ613D-B diagnostic monitor also has a Focus View Mode, which allows radiologists to highlight a key part of an image, and a Multi-Resolution Mode, which facilitates resolution adjustments to optimize viewing of different images, according to LG.
"LG's new 5MP diagnostic monitor is tailored for reviewing mammograms and breast tomosynthesis, providing a high-quality medical imaging display with both simple management and practical features for users,” said Stephen K. Hu, the head of medical displays for LG Business Solutions USA. “We’re dedicated to providing cutting-edge solutions for the medical sector with our display technologies, and the addition of the latest 5MP monitor underscores this commitment to innovation.”
Mammography Study: Can Stand-Alone AI Enhance Detection of Interval Breast Cancer?
August 28th 2024Identifying over 23 percent of interval breast cancers with a 96 percent sensitivity in mammography interpretation, an emerging AI software also facilitated correct localization in over 75 percent of cases involving interval breast cancer, according to new research.
Can AI Facilitate Effective Triage for Supplemental Breast MRI After Negative Mammography Screening?
July 10th 2024The AISmartDensity software facilitated a cancer detection rate (CDR) with breast MRI that was nearly four times higher than the CDR previously reported in trials involving traditional breast density assessment.
Mammography and Breast MRI: Is it Time to Evaluate Strategies as Opposed to Modalities?
July 5th 2024The combination of mammography with breast MRI within 90 days had a 96.2 percent sensitivity in comparison to 48.1 percent for mammography and 79.7 percent for breast MRI performed within 91 to 270 days after index mammography, according to newly published research.
